Table 6. The molecular differences between genders in GC patients after curative surgery.

	All GC				Stage I GC				Stage II GC				Stage III GC
	Male n=309 n (%)	Female n=129 n (%)	P value		Male n=49 n (%)	Female n=39 n (%)	P value		Male n=90 n (%)	Female n=35 n (%)	P value		Male n=170 n (%)	Female n=55 n (%)	P value
MSI status			0.355				0.033				0.106				0.115
MSI-L/S	284 (91.9)	116 (89.1)			47 (95.9)	32 (82.1)			85 (94.4)	30 (85.7)			152 (89.4)	53 (96.4)
MSI-H	25 (8.1)	14 (10.9)			2 (4.1)	7 (17.9)			5 (5.6)	5 (14.3)			18 (10.6)	2 (3.6)
PD-L1 expression	96 (31.1)	26 (20.2)	0.020		14 (28.6)	8 (20.5)	0.386		28 (31.1)	9 (25.7)	0.553		53 (31.2)	9 (16.4)	0.033
PIK3CA amplification	137 (44.3)	69 (53.5)	0.080		20 (40.8)	19 (48.7)	0.459		39 (43.3)	19 (54.3)	0.270		78 (45.9)	31 (56.4)	0.176
Genetic mutations
PI3K/AKT pathway	54 (17.5)	16 (12.4)	0.182		8 (16.3)	4 (10.3)	0.410		15 (16.7)	5 (14.3)	0.744		31 (18.3)	7 (12.7)	0.335
TP53	42 (13.6)	20 (15.5)	0.601		6 (12.2)	7 (17.9)	0.454		11 (12.2)	1 (2.9)	0.111		25 (14.7)	12 (21.8)	0.216
ARID1A	42 (13.6)	10 (7.8)	0.085		7 (14.3)	4 (10.3)	0.570		13 (14.4)	2 (5.7)	0.177		22 (12.9)	4 (7.3)	0.253
BRAF	2 (0.6)	0	0.360		1 (2.0)	0	0.370		1 (1.1)	0	0.531		0	0	-
KRAS	4 (1.3)	6 (4.7)	0.071		2 (4.1)	2 (5.1)	0.815		2 (2.2)	2 (5.7)	0.319		0	2 (3.6)	0.059

MSI: microsatellite instability; MSI-H: MSI-high; MSI-L/S: MSI-low/stable; bold: statistically significant.